NONOF NOVO NORDISK A S
Price Chart
Executive Summary
Novo Nordisk announced that the EMA's CHMP has adopted a positive opinion recommending EU marketing authorization for Wegovy 7.2 mg in a convenient single-dose pen. The product is already approved in the US and UK, and EU launch is expected in Q3 2026. STEP UP trial data showed 20.7% mean weight loss, with about one-third of patients achieving ≥25% weight loss, reinforcing the drug's efficacy profile.
Actionable Insight
The CHMP positive opinion is a clear regulatory catalyst that removes EU approval risk for the 7.2 mg single-dose pen. Competitors face a higher efficacy bar given the 20.7% weight loss data. Monitor final EC approval (typically follows CHMP recommendation within 2-3 months) and launch execution in Q3 2026. Competitive positioning strengthens versus Lilly's tirzepatide as oral GLP-1 access expands.
Key Facts
- CHMP recommended EU approval of Wegovy 7.2 mg in a single-dose pen for people living with obesity
- STEP UP trial demonstrated 20.7% mean weight loss (efficacy estimand) with semaglutide 7.2 mg
- Approximately 1 in 3 patients achieved 25% or greater weight loss in STEP UP
- Wegovy 7.2 mg is already approved in US (as Wegovy HD) and UK
- EU launch expected in Q3 2026
- In STEP UP T2D, mean weight loss was 14.1% in patients with obesity and type 2 diabetes
Financial Impact
This expands the addressable EU market for the higher-dose Wegovy formulation with a more convenient single-dose pen, likely driving incremental revenue from Q3 2026. No specific dollar amounts disclosed.
Risk Factors
- Final European Commission approval is not guaranteed despite CHMP positive opinion
- Pricing and reimbursement negotiations across EU member states could limit volume uptake
- Competition from oral GLP-1s and next-gen obesity treatments may intensify
- Manufacturing capacity constraints could delay launch scale-up
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003645 |
| Document: 0001171843-26-003645-index-headers.html | 0001171843-26-003645 |
| Document: 0001171843-26-003645-index.html | 0001171843-26-003645 |
| Document: 0001171843-26-003645.txt | 0001171843-26-003645 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 27, 2026
10d ago
|
6-K
| — | awaiting T+5 | — | — |
|
May 22, 2026
15d ago
|
6-K
| $43.80 $44.29 | ▲ +1.12% | ▼ −0.54% | $43.36 (−1.00%) |
|
Apr 13, 2026
7w ago
|
6-K
| $38.08 $39.71 | ▲ +4.28% | ▲ +0.98% | $43.36 (+13.87%) |
|
Apr 7, 2026
8w ago
|
6-K
| $35.92 $38.82 | ▲ +8.07% | ▲ +2.74% | $43.36 (+20.71%) |
|
Mar 27, 2026
10w ago
|
6-K
| $35.29 $35.58 | ▲ +0.82% | ▼ −3.04% | $43.36 (+22.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access